The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kasikhina E.I.

State Educational Institution of additional professional education "Russian Academy of Continuous Medical Education"

Glazko I.I.

State Educational Institution of Additional Professional Education «Russian Medical Academy of Postgraduate Education»

Chekmarev A.S.

FGBU "Uchebno-nauchnyĭ meditsinskiĭ tsentr Upravleniia delami Prezidenta RF"

Herpetic infection: mechanisms of latency and reactivation. Potential to control the infection

Authors:

Kasikhina E.I., Glazko I.I., Chekmarev A.S.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2014;12(1): 75‑80

Read: 4798 times

Download PDF (RU)
Contact the author
Table of contents

HERPETIC INFECTION: MECHANISMS OF LATENCY AND REACTIVATION. POTENTIAL TO CONTROL THE INFECTION
HERPETIC INFECTION: MECHANISMS OF LATENCY AND REACTIVATION. POTENTIAL TO CONTROL THE INFECTION

To cite this article:

Kasikhina EI, Glazko II, Chekmarev AS. Herpetic infection: mechanisms of latency and reactivation. Potential to control the infection. Russian Journal of Clinical Dermatology and Venereology. 2014;12(1):75‑80. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Herpes infe­ction and primary cere­bral vasculitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(2):39-44
Abstract:

The potential mechanisms that regulate the latency and limit reactivation of herpesviruses are analyzed. The relations between the herpes virus and the host immune system are described. Factors contributing to maintaining the latent infection and reactivation of viral replication are discussed. The use of acyclic nucleosides, including valacyclovir, is one of the strategies to control viral replication. The study involved 10 women with recurrent genital herpes accompanied by symptoms of persistent genital itching. The clinical effect (elimination of itching) was achieved in 8 patients by applying the complex antiviral therapy with drugs Virdel (valacyclovir) and Lavomax (tilorone hydrochloride) for 12 weeks.

Keywords:

herpes infection
latency
reactivation
valacyclovir (Virdel)
Tilorone (Lavomax)

Authors:

Kasikhina E.I.

State Educational Institution of additional professional education "Russian Academy of Continuous Medical Education"

Glazko I.I.

State Educational Institution of Additional Professional Education «Russian Medical Academy of Postgraduate Education»

Chekmarev A.S.

FGBU "Uchebno-nauchnyĭ meditsinskiĭ tsentr Upravleniia delami Prezidenta RF"

Close metadata

References:

  1. Vol'f K., Goldsmit L.A., Kats S.I., et al. Dermatologiya Fitspatrika v klinicheskoy praktike. Pod red. akad. A.A. Kubanovoy. [Fitzpatrick's Dermatology in clinical practice. Ed. by Acad. A.A. Kubanova] Moscow: Izd. Panfilova, BINOM. Laboratoriya znaniy 2012. vol. 3; 2043-2056 (In Russian).
  2. Babel N., Brestrich G., Gondek L.P. et al. Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes. J Am Soc Nephrol 2009; 20: 344-352.
  3. Wallace M.E., Keating R., Heath W.R. et al. The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J Virol 1999; 73: 7619-7626.
  4. Okano M., Thiele G.M., Davis J.R. et al. Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev 1988; 1: 300-312.
  5. Glaser R., Strain E.C., Tarr K.L. et al. Changes in Epstein-Barr virus antibody titers associated with aging. Proc Soc Exp Biol Med 1985; 179: 352-355.
  6. Weymouth L.A., Gomolin I.H., Brennan T. et al. Cytomegalovirus antibody in the elderly. Intervirology 1990; 31: 223-229.
  7. Stowe R.P., Kozlova E.V., Yetman D.L., Walling D.M., Goodwin J.S., Glaser R. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol 2007; 42 (6): 563-570.
  8. Stowe R.P., Peek M.K., Cutchin M.P., Goodwin J.S. Reactivation of Herpes Simplex Virus Type 1 is Associated with Cytomegalovirus and Age. J Med Virol 2012; 84(11): 1797-1802.
  9. Glaser R., Kiecolt-Glaser J.K. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 2005; 5: 243-251.
  10. Glaser R., Pearl D.K., Kiecolt-Glaser J.K., Malarkey W.B. Plasma cortisol levels and reactivation of latent Epstein-Barr virus in response to examination stress. Psychoneuroendocrinology 1994; 19: 765-772.
  11. Mehta S.K., Cohrs R.J., Forghani B. et al. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol 2004; 72: 174-179.
  12. Stowe R.P., Mehta S.K., Ferrando A.A. et al. Immune responses and latent herpesvirus reactivation in spaceflight. Aviat Space Environ Med 2001; 72: 884-891.
  13. Freeman M.L., Sheridan B.S., Bonneau R.H., Hendricks R.L. Psychological stress compromises CD8+ T cell control of latent herpes simplex virus type 1 infections. J Immunol 2007; 179: 322-328.
  14. Turnbull A.V., Rivier C. Regulation of the HPA axis by cytokines. Brain Behav Immun 1995; 9(4): 253-275.
  15. Noisakran S., Halford W.P., Veress L., Carr D.J. Role of the hypothalamic pituitary adrenal axis and IL-6 in stress-induced reactivation of latent herpes simplex virus type 1. J Immunol 1998; 160: 5441-5447.
  16. Nicholas J. Human gammaherpesvirus cytokines and chemokine receptors. J Interferon Cytokine Res 2005; 25: 373-383.
  17. Mocarski E.S. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 2004; 6: 707-717.
  18. Jochum S., Moosmann A., Lang S., Hammerschmidt W., Zeidler R. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog 2012; 8(5): e1002704.
  19. Staras S.A., Dollard S.C., Radford K.W. et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43: 1143-1151.
  20. Cannon M.J., Schmid D.S., Hyde T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20(4): 202-213.
  21. Gillespie G.M., Wills M.R., Appay V. et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000; 74: 8140-8150.
  22. Khan N., Hislop A., Gudgeon N. et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004; 173: 7481-7489.
  23. Pawelec G., Akbar A., Caruso C. et al. Is immunosenescence infectious? Trends Immunol 2004; 25: 406-410.
  24. Almanzar G., Schwaiger S., Jenewein B., Keller M. et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 2005; 79: 3675-3683.
  25. Bennett J.M., Glaser R., Malarkey W.B., Beversdorf D.Q. et al. Inflammation and reactivation of latent herpesviruses in older adults. Brain Behav Immun 2011; 26: 739-746.
  26. Trzonkowski P., Mysliwska J., Szmit E., Wieckiewicz J. et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of immunosenescence. Vaccine 2003; 21: 3826-3836.
  27. Wikby A., Ferguson F., Forsey R. et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005; 60: 556-565.
  28. Wikby A., Nilsson B.O., Forsey R. et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev 2006; 127: 695-704.
  29. Waldman W.J., Williams M.V., Jr, Lemeshow S. et al. Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: evidence for depression-induced atherosclerotic risk. Brain Behav Immun 2008; 22: 215-223.
  30. Strandberg T.E., Pitkala K.H, Linnavuori K.H. et al. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke 2003; 34: 2126-2131.
  31. Voorend M., van der Ven A.J., Kubat B. Limited role for C. pneumoniae, CMV and HSV-1 in cerebral large and small vessel atherosclerosis. Open Neurol J 2008; 2: 39-44.
  32. Nabipour I., Vahdat K., Jafari S.M. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: the Persian Gulf Healthy Heart Study. Cardiovasc Diabetol 2006;5: 25.
  33. Aiello A.E., Haan M., Blythe L. et al. The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc 2006; 54: 1046-1054
  34. Lurain N.S., Robert E.S., Xu J., Camarca M., Landay A., Kovacs A.A., Reichelderfer P.S. HIV Type 1 and Cytomegalovirus Coinfection in the Female Genital Tract. J Infect Dis 2004; 190 (3): 619-623.
  35. Aynaud O., Poveda J.D., Huynh B. et al. Frequency of herpes simplex virus, cytomegalovirus and human papillomavirus DNA in semen. Int J STD AIDS 2002; 13(8): 547-550.
  36. Abou M., Dällenbach P. Acute cervicitis and vulvovaginitis may be associated with Cytomegalovirus. BMJ Case Rep 2013. pii: bcr2013008884. doi: 10.1136/bcr-2013-008884.
  37. Marchenko L.A., Lushkova I.P. Genital'nyy gerpes i nositel'stvo antigenov glavnogo kompleksa gistosovmestimosti klassa I. [Genital herpes and carrier antigens major histocompatibility complex class I] Ros zhurn kozhn i ven bol 2009; 2: 4-11 (In Russian).
  38. Zhao Y., Cao X., Zheng Y. et al. Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2. J Med Virol 2012; 84(12): 1920-1927.
  39. Ormrod D., Scott L.J., Perry C.M. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 2000; 59(4): 839-863.
  40. Perti T. , Saracino M., Baeten J.M. et al. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. J Acquir Immune Defic Syndr 2013; 63(2): 201-208.
  41. Gupta R., Wald A., Krantz E. et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004; 190(8): 1374-1381.
  42. Letyaeva O.I., Gizinger O.A., Ziganshin O.R. Genital'nyy gerpes: dolgosrochnye podkhody k terapii "pozhiznennoy infektsii" [Genital herpes: long-term approaches to therapy of lifelong infection] (In Russian).
  43. Ginekologiya. Natsional'noe rukovodstvo / Pod red. V.I. Kulakova, G.M. Savel'evoy, I.B. Manukhina. [Gynecology. National guidelines / Ed. by V.I. Kulakov, G.M. Savel'eva, I.B. Manukhin] Moscow: GEOTAR-Media 2009: 1088 (In Russian).
  44. Letyaeva O.I., Gizinger O.A., Ziganshin O.R. Voprosy effektivnosti i bezopasnosti immunomoduliruyushchey terapii v lechenii khlamidiyno-gerpeticheskoy infektsii urogenital'nogo trakta. [The effectiveness and safety of therapies in treatment of chlamydial and herpetic infection of the urogenital tract] Vestn dermatol i venerolog 2012; 1: 99-104 (In Russian).
  45. Scrots'ka O.L., Zholobak N.M., Antonenko S.V., Spivak Mla, Karpov O.V. Antiherpetic effect of RNA-tilorone molecular complex in cell culture. Microbiol Z 2007; 69(3): 62-68.
  46. Udzhukhu V.Yu. Opyt kompleksnogo lecheniya genital'nogo gerpesa u zhenshchin. [Experience in comprehensive treatment of genital herpes in women] Akush i ginekol 2011; 8: 95-97 (In Russian).
  47. Sarvilina I.V. Issledovanie effektivnosti i bezopasnosti primeneniya tilorona v terapii retsidiviruyushchego labial'nogo gerpesa u vzroslykh. [Study of the efficacy and safety of tilorone therapy of recurrent herpes labialis in adults] Lech vrach 2013; 10: 85-90 (In Russian).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.